证券代码：603079 证券简称：圣达生物 公告编号：2025-051 浙江圣达生物药业股份有限公司 关于召开2025年半年度业绩说明会的公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 09 月 15 日（星期一）11:00-12:00 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 09 月 08 日（星期一）至 09 月 12 日(星期五)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 zqb@sd-pharm.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行 回答。 浙江圣达生物药业股份有限公司（以下简称"公司"）已于 2025 年 08 月 26 日发布公司 2025 年半年度报告，为便于广大投资者更全面深入地了解公司 2025 年半年度经营成果、财务状况，公司计划于 2025 年 09 月 15 日（星期一） 11:00-12:00 举行 2025 年半年度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本 ...

Meeting Details - The third extraordinary general meeting of shareholders for Zhejiang Shengda Biological Pharmaceutical Co., Ltd. will be held on September 10, 2025, at 14:00 [1] - The meeting will take place at the company's conference room located at 18 Shifeng East Road, Fuxi Street, Tiantai County, Zhejiang Province [1] - Voting will be conducted both on-site and via the Shanghai Stock Exchange network voting system during specified time slots on the same day [2] Meeting Procedures - The meeting will follow the company's articles of association and relevant laws to ensure order and efficiency [1] - Shareholders must present identification and relevant documents to attend the meeting [2] - Non-cumulative voting will be used, with each share granting one vote [3] Agenda Items - The primary agenda item is the appointment of the auditing firm for the fiscal year 2025 [4] - The company proposes to appoint Grant Thornton (Zhonghua) Certified Public Accountants LLP as the new auditor, replacing Tianjian Certified Public Accountants [7] - The proposed audit fee for 2025 is set at 1.1 million yuan, which includes 1 million yuan for financial report auditing and 100,000 yuan for internal control auditing [6] Auditor Background - Grant Thornton was established in 1981 and has a significant number of partners and registered accountants [4] - The firm has a total revenue of 2.614 billion yuan, with 2.103 billion yuan from audit services [4] - The company has had no criminal penalties against its auditors in the past three years, with minimal administrative penalties [6] Transition of Auditors - The change in auditors is based on the need for fresh perspectives and expertise as the company grows [7] - Both the outgoing and incoming auditors have been informed of the transition, and there are no objections [8] - The transition is expected to have no negative impact on the annual audit process [8]

证券代码：603079 浙江圣达生物药业股份有限公司 2025 年第三次临时股东大会会议材料 二〇二五年九月 浙江圣达生物药业股份有限公司 2025 年第三次临时股东大会会议材料 | 目录 | | --- | | 2025 年第三次临时股东大会会议议程 | | 1 | | --- | --- | --- | | 2025 年第三次临时股东大会会议须知 | | 3 | | 议案一:关于公司聘任 2025 | 年度审计机构的议案 | 5 | 浙江圣达生物药业股份有限公司 2025 年第三次临时股东大会会议材料 浙江圣达生物药业股份有限公司 2025 年第三次临时股东大会会议议程 一、会议时间 现场会议：2025 年 9 月 10 日(星期三)下午 14:00 浙江省天台县福溪街道始丰东路 18 号，浙江圣达生物药业股份 有限公司会议室。 三、会议召集人 浙江圣达生物药业股份有限公司董事会 四、会议审议事项 1.审议《关于公司聘任 2025 年度审计机构的议案》。 五、会议流程 1、与会人员签到； 2、大会主持人宣布会议开始，介绍本次股东大会的出席情况； 网络投票：2025 年 9 月 10 日(星期三)采用上海证 ...

证券代码：603079 证券简称：圣达生物 公告编号：2025-050 浙江圣达生物药业股份有限公司 关于使用闲置募集资金进行现金管理的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 ● 特别风险提示 尽管公司使用闲置募集资金进行现金管理购买的产品属于低风险投资品种，总体风险可控，但金融市场 受宏观经济的影响较大，不排除该项投资受到市场波动的影响，存在一定的系统性风险。公司将积极采 取相关措施防范和控制投资风险，敬请广大投资者注意投资风险。 一、投资情况概述 （一）投资目的 为提高募集资金使用效率，合理利用暂时闲置募集资金，在确保不影响募集资金投资项目建设和使用、 募集资金安全的情况下，增加公司的收益，为公司及股东获取更多回报。 （二）投资金额 重要内容提示： ● 基本情况 浙江圣达生物药业股份有限公司（以下简称"公司"）于2025年7月7日召开第四届董事会第十八次会议和 第四届监事会第十六次会议，审议通过了《关于使用闲置募集资金进行现金管理的议案》，同意公司及 子公司使用额度不超过人民币23,000.00万元的暂时 ...

证券代码：603079 证券简称：圣达生物 公告编号：2025-050 浙江圣达生物药业股份有限公司 关于使用闲置募集资金进行现金管理的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 基本情况 | 投资金额 | 8,000.00 万元 | | --- | --- | | 投资种类 | 中国建设银行浙江分行单位人民币定制型结构性存款 | | 资金来源 | 募集资金 | 已履行及拟履行的审议程序 浙江圣达生物药业股份有限公司（以下简称"公司"）于 2025 年 7 月 7 日召 开第四届董事会第十八次会议和第四届监事会第十六次会议，审议通过了《关于 使用闲置募集资金进行现金管理的议案》，同意公司及子公司使用额度不超过人 民币 23,000.00 万元的暂时闲置募集资金进行现金管理，用于购买安全性高、流 动性好、有保本约定、产品期限不超过 12 个月的银行等金融机构现金管理产品 （包括但不限于结构性存款、大额存单等）。在上述期限及额度内，资金可滚动 使用，并授权公司董事长最终审定并签署相关实施协议或者合同等 ...

Core Viewpoint - The financial performance of Shengda Bio (603079) shows significant growth in net profit and profitability metrics for the first half of 2025 compared to the same period in 2024, indicating a positive trend in the company's operations and financial health [1] Financial Performance Summary - Total revenue for the first half of 2025 reached 401 million yuan, a year-on-year increase of 4.23% [1] - Net profit attributable to shareholders was 37.81 million yuan, up 129.2% year-on-year [1] - Gross margin improved to 27.83%, reflecting a 39.11% increase year-on-year [1] - Net margin rose to 10.11%, showing a 99.47% increase year-on-year [1] - Earnings per share increased to 0.22 yuan, a 120.0% rise compared to the previous year [1] Cost and Expense Analysis - Total selling, administrative, and financial expenses amounted to 36.46 million yuan, accounting for 9.1% of revenue, which is a 4.97% increase year-on-year [1] - Operating costs decreased by 5.96%, attributed to improved operational efficiency and cost optimization [6] Cash Flow and Capital Structure - Cash flow from operating activities saw a significant increase of 97.59%, driven by higher cash receipts from sales [8] - The company raised 61.23% in cash and cash equivalents due to issuing shares to specific investors [1][10] - Short-term borrowings decreased by 100% as the company repaid due bank loans [3] Investment and R&D - R&D expenses increased by 22.39%, indicating a commitment to innovation and product development [7] - The company has been focusing on expanding its market presence in biological preservatives and functional ingredients, contributing to revenue growth [6] Asset and Liability Management - The company’s monetary funds increased by 114.52% to 509 million yuan, reflecting strong liquidity [1] - Accounts receivable decreased by 3.82%, indicating improved collection efficiency [1] - Long-term liabilities increased by 26.79%, suggesting a rise in financial leverage [1] Business Model and Market Position - The company’s return on invested capital (ROIC) was reported at 2.05%, indicating challenges in capital efficiency [11] - The business model relies heavily on R&D and capital expenditures, necessitating careful evaluation of capital projects [11]

Core Viewpoint - The company, Zhejiang Shengda Biological Pharmaceutical Co., Ltd., is undergoing a change in its auditing firm for the 2025 fiscal year, transitioning from Tianjian Accounting Firm to RSM China (致同会计师事务所) due to the need for fresh auditing perspectives and compliance with regulations [4][11]. Group 1: Company Overview - The company is identified by the stock code 603079 and is referred to as Shengda Biological [3]. - The company has confirmed that there are no changes in its controlling shareholders or actual controllers during the reporting period [2]. Group 2: Financial Data - The company raised a total of RMB 267.61 million through a stock issuance, with a net amount of RMB 261.42 million after deducting issuance costs [48]. - The average selling price of the company's main products, vitamins, increased by 45.78% year-on-year and 4.98% quarter-on-quarter in the second quarter [57]. Group 3: Audit Firm Change - The new auditing firm, RSM China, has been selected based on its professional competence and experience in providing auditing services to listed companies [11][12]. - The previous auditing firm, Tianjian, provided standard unqualified opinions for the 2024 financial report [11]. - The change in auditing firms was communicated to both the outgoing and incoming firms, with no objections raised [4][11]. Group 4: Shareholder Meeting - The third extraordinary general meeting of shareholders is scheduled for September 10, 2025, to discuss the appointment of the new auditing firm [15][14]. - The voting for the shareholder meeting will be conducted through both on-site and online methods [15][16]. Group 5: Fund Management - The company has established a management system for the raised funds, ensuring they are stored in dedicated accounts and managed according to regulatory requirements [50][51]. - There were no instances of using idle raised funds for temporary working capital during the reporting period [55].

Core Viewpoint - The report highlights the financial performance and operational strategies of Shengda Bio-Pharm Co., Ltd. for the first half of 2025, showcasing significant growth in revenue and profit driven by enhanced management practices and market expansion in the vitamin and bio-preservative sectors [1][3]. Financial Performance - The company's operating income for the first half of 2025 reached approximately 400.73 million RMB, representing a 4.23% increase compared to the same period last year [3]. - Total profit amounted to approximately 50.27 million RMB, a substantial increase of 107.77% year-on-year [3]. - The net profit attributable to shareholders was approximately 37.81 million RMB, reflecting a 129.20% increase compared to the previous year [3]. - The net cash flow from operating activities was approximately 22.96 million RMB, up 97.59% from the previous year [3]. Industry Overview - The vitamin industry in China is experiencing steady growth, with the country being a major global producer of various vitamins, including biotin and folic acid [6][8]. - The bio-preservative and functional ingredient market is expanding rapidly, driven by increasing consumer demand for natural and safe food additives [6][8]. - The report indicates that the domestic vitamin market faced price declines in the first half of 2025, but the overall demand remains stable [6][8]. Company Positioning - Shengda Bio-Pharm is recognized as one of the leading suppliers of biotin and folic acid in China, ranking among the top five suppliers of biotin and top four suppliers of folic acid in 2024 [6][8]. - The company is one of the few in China capable of producing multiple types of bio-preservatives, including nisin and natamycin, and is a key player in setting industry standards [6][8]. - Shengda Bio-Pharm has established a strong reputation in the market, supported by long-term partnerships with major domestic and international clients [11][12]. Operational Strategies - The company employs a "sales-driven production" model, optimizing procurement and production processes to enhance efficiency and reduce costs [7][8]. - Shengda Bio-Pharm has invested in smart manufacturing technologies to improve product consistency and operational efficiency [7][8]. - The company is focused on continuous innovation and R&D, with a significant increase in R&D expenditure by 22.39% in the first half of 2025 [3][8]. Market Expansion - The company has successfully registered its biotin products in India, the EU, and South Korea, paving the way for entry into higher-end pharmaceutical markets [8][9]. - Shengda Bio-Pharm's subsidiaries have shown strong performance, with significant sales growth in key products such as lactic acid bacteria and natamycin [8][9].

Core Viewpoint - Zhejiang Sandar Biopharmaceutical Co., Ltd. reported significant growth in its financial performance for the first half of 2025, with notable increases in total assets, revenue, and net profit compared to the previous year [1]. Financial Performance - Total assets reached approximately CNY 2.11 billion, an increase of 18.43% from the end of the previous year [1]. - Operating revenue for the period was approximately CNY 400.73 million, reflecting a growth of 4.23% year-on-year [1]. - Total profit amounted to approximately CNY 50.27 million, representing a substantial increase of 107.77% compared to the same period last year [1]. - Net profit attributable to shareholders was approximately CNY 35.06 million, which is a remarkable increase of 580.57% year-on-year [1]. Shareholder Information - The total number of shareholders as of the reporting period was 17,587 [2]. - The largest shareholder, Zhejiang Sandar Group Co., Ltd., holds 24.00% of the shares, amounting to 45,375,792 shares [2]. - Other significant shareholders include Tian Tai Wan Jian Investment Development Center and Zhejiang Hongbo Enterprise Management Co., Ltd., holding 15.20% and 6.36% of shares, respectively [2].

Group 1 - The board of directors of Zhejiang Shengda Biological Pharmaceutical Co., Ltd. held its 19th meeting on August 22, 2025, with all 9 directors present, confirming the legality and validity of the meeting procedures [1][2] - The board approved the 2025 semi-annual report and summary, which had been reviewed by the audit committee [2] - The board also approved the proposal for the appointment of the auditing institution for the year 2025, which will be submitted to the shareholders' meeting for further approval [2][3] Group 2 - The board reviewed and approved the special report on the storage and use of raised funds for the first half of 2025, with unanimous support from all directors [2] - A proposal to convene the third extraordinary general meeting of shareholders in 2025 was also approved, with all directors voting in favor [3]